Needham & Company LLC Reiterates Hold Rating for Amicus Therapeutics (NASDAQ:FOLD)

Needham & Company LLC reissued their hold rating on shares of Amicus Therapeutics (NASDAQ:FOLD - Free Report) in a research report report published on Thursday morning,Benzinga reports.

Other equities analysts have also issued reports about the stock. StockNews.com lowered shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Thursday, October 31st. Bank of America lifted their price target on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a "buy" rating in a research note on Thursday, October 17th. Morgan Stanley decreased their price objective on shares of Amicus Therapeutics from $19.00 to $18.00 and set an "overweight" rating on the stock in a report on Friday, October 11th. JPMorgan Chase & Co. cut their price target on shares of Amicus Therapeutics from $17.00 to $16.00 and set an "overweight" rating for the company in a report on Friday, August 16th. Finally, Jefferies Financial Group started coverage on Amicus Therapeutics in a research report on Friday, September 6th. They issued a "buy" rating and a $18.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, Amicus Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $17.50.

Amicus Therapeutics Price Performance

FOLD stock traded down $0.27 during trading on Thursday, hitting $10.97. The company had a trading volume of 2,920,365 shares, compared to its average volume of 2,725,524. Amicus Therapeutics has a fifty-two week low of $9.02 and a fifty-two week high of $14.57. The firm has a market capitalization of $3.25 billion, a price-to-earnings ratio of -27.95 and a beta of 0.68. The business has a 50 day moving average of $11.15 and a 200 day moving average of $10.61. The company has a current ratio of 2.75, a quick ratio of 2.26 and a debt-to-equity ratio of 2.93.

Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.05). Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The firm had revenue of $126.67 million during the quarter, compared to analysts' expectations of $121.21 million. During the same period in the prior year, the company posted ($0.15) earnings per share. Amicus Therapeutics's revenue for the quarter was up 34.0% on a year-over-year basis. As a group, research analysts predict that Amicus Therapeutics will post -0.06 earnings per share for the current year.

Insider Transactions at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction on Friday, November 1st. The shares were sold at an average price of $11.46, for a total transaction of $85,950.00. Following the transaction, the chief executive officer now owns 886,654 shares in the company, valued at $10,161,054.84. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last three months, insiders have sold 22,500 shares of company stock valued at $253,275. Insiders own 2.20% of the company's stock.

Institutional Investors Weigh In On Amicus Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Assenagon Asset Management S.A. bought a new position in shares of Amicus Therapeutics during the 2nd quarter worth approximately $8,386,000. M&G Plc grew its holdings in shares of Amicus Therapeutics by 12.4% during the second quarter. M&G Plc now owns 748,451 shares of the biopharmaceutical company's stock worth $7,485,000 after buying an additional 82,728 shares in the last quarter. Edgestream Partners L.P. boosted its position in Amicus Therapeutics by 1,290.4% during the first quarter. Edgestream Partners L.P. now owns 270,164 shares of the biopharmaceutical company's stock worth $3,183,000 after acquiring an additional 250,734 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its holdings in shares of Amicus Therapeutics by 7.8% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 100,538 shares of the biopharmaceutical company's stock worth $1,183,000 after purchasing an additional 7,304 shares during the last quarter. Finally, Fiera Capital Corp grew its holdings in Amicus Therapeutics by 1.1% in the 2nd quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company's stock valued at $52,382,000 after buying an additional 58,113 shares in the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.